Operations • Successful in vitro studies completed on GeneICE therapeutics platform • GeneICE™ patents granted in Europe and the USA • Creation of diagnostics commercialisation business, ValiBIO SA • European patent rights secured on Nucleosomics™, a high throughput screening mechanism for a wide range of cancers • Solid progress made on HyperGenomics™, high throughput screening mechanism for acute myeloid leukemia and prostate cancer, Post year end • GeneICE™ studies with VAL 101 showing positive results in in vivo model of pancreatic cancer • Therapeutics portfolio broadened with development of a second GeneICE™ anti-cancer molecule • GeneICE™ IP cover extended with patents granted in Australia • European distribution rights secured for proven HPV test kit technology • Successful completion of a funding round on 12 May 2008; raising £830,000 net cash proceeds for the Company
Dr Satu Vainikka, Chief Executive, commented: “We are pleased with the operational progress achieved by ValiRx in 2007 and encouraged by the deepening commercial relationships we have established. We are looking forward to generating first commercial revenues from our diagnostics portfolio in early 2009 and to progressing our first therapeutics programmes towards the clinic. Our positive progress was reflected in the successful closing of our funding round in May 2008.”
